Retatrutide-Associated Pain and Hypersensitivity
Retatrutide has been associated with nonspecific treatment-emergent pain syndromes, including overall “pain” and dysesthesia, in clinical trials. [1], [2] Ankle pain is not specifically listed in trial safety tables found in the cited sources, but localized lower-extremity pain could occur under the broader category of systemic pain or dysesthesia. [1]
Adverse-Event Findings Relevant to Ankle Pain
- In a phase 3 trial in type 2 diabetes, “pain” occurred in 2% (4 mg), 4% (9 mg), and 3% (12 mg) of participants versus 8% with placebo. [1]
- In the same phase 3 trial, “back pain” occurred in 3% (4 mg), 2% (9 mg), and 1% (12 mg) versus 7% with placebo. [1]
- In the same phase 3 trial, dysesthesia occurred in 4% (4 mg), 2% (9 mg), and 4% (12 mg) versus 0% with placebo. [1]
Injection-Site Pain and Local Reactions
Retatrutide has also been associated with injection-site pain and injection-site reactions in safety reporting for GLP-1 products. [2]
Practical Clinical Interpretation
Localized ankle pain after starting retatrutide is compatible with reported broader categories such as “pain” or “dysesthesia,” but trial reports do not establish a specific causal link to ankle pain by anatomic site. [1]
Escalation for Safety Concerns
Medical assessment is recommended for severe or rapidly worsening ankle pain, pain with significant swelling or redness, or symptoms suggesting an allergic or systemic reaction. [2] Reporting suspected adverse events to regulatory systems is recommended when clinically significant symptoms occur. [2]